Gluconeogenesis, But Not Glycogenolysis, Contributes to the Increase in Endogenous Glucose Production by SGLT-2 Inhibition.
Peter WolfPaul FellingerLorenz PflegerHannes BeiglböckPatrik KrumpolecChiara BarbieriFrancesco RubinoJürgen HarreiterMatthäus MetzThomas SchererMaximilian ZeydaSabina Baumgartner-ParzerRodrig MarculescuSiegfried TrattnigAlexandra Kautzky-WillerMartin KrššákMichael R KrebsPublished in: Diabetes care (2020)
The rise in EGP after SGLT-2 inhibition is due to increased gluconeogenesis, but not glycogenolysis. Changes in glucagon and the insulin-to-glucagon ratio are not associated with an increased hepatic glycogen breakdown. HCL and kATP are not significantly affected by a single dose of dapagliflozin.